ImmuneRegen has reported positive results from a study that evaluated its lead anti-Influenza drug, Homspera. The study in animals infected with H5N1 (Avian) Influenza virus, revealed that Homspera
Novavax has begun a Phase IIa clinical study of its trivalent seasonal influenza VLP vaccine candidate in healthy adults 60 years of age or older. The company said
Cerimon Pharmaceuticals has acquired exclusive rights to develop and commercialise diclofenac sodium patch in Europe, including most countries in the the EU, Turkey, Switzerland, Norway, the Balkan countries
Sanofi-aventis and Regeneron Pharmaceuticals (Regeneron) have entered into agreements to expand and extend their existing global collaboration to discover, develop, and commercialise fully-human therapeutic monoclonal antibodies. Both the
Aastrom Biosciences will initiate its second clinical trial for the treatment of dilated cardiomyopathy (DCM), after a positive 30-day review of Aastrom’s Investigational New Drug (IND) submission by
Trin Pharma (Trin) has reported that BfArM, the German Regulatory Authority, has approved the start of a Phase I clinical trial of TRIN 2755 in solid tumors. The
Teva Pharmaceutical has reported that the US District Court for the District of Delaware has issued a decision in its litigation over the company’s Abbreviated New Drug Application
Thermo Fisher believes that Inverness Medical’ decision to terminate the contract and sell direct to customers was made in response to the company’s recent strategic decision to expand
Mylan has reported that its privately held Indian subsidiary, Matrix Laboratories, has received final approval from the FDA for its Abbreviated New Drug Application (ANDA) for Lansoprazole delayed-release
Sigma-Aldrich has entered into an exclusive worldwide distribution agreement with Stemgent, to offer Stemgent’s portfolio of lentivirus-based delivery systems for the generation of induced pluripotent stem (iPS) cells.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.